title: Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients.
abstract: Mosapride citrate is a novel selective 5-HT4 receptor agonist. It facilitates acetylcholine release from the enteric cholinergic neurons. In contrast to cisapride, mosapride does not block K(+) channels or D2 dopaminergic receptors. The objective of this study is to perform an open study of mosapride citrate's effects on constipation, a prominent lower gastrointestinal tract disorder in parkinsonian patients. A total of 14 parkinsonian patients (7 with Parkinson's disease, 7 with multiple system atrophy; 10 men, 4 women; mean age, 67 years) with constipation (10 with bowel movement < 3 times/week; 14 with difficulty in defecation) were treated with 15 mg/day of mosapride citrate for 3 months. Pre- and posttreatment objective parameters in colonic transit time (CTT) and rectoanal videomanometry were obtained. Statistical analysis was made by Student's t test. Mosapride was well tolerated by all patients except for 1, who discontinued use of the drug because of epigastric discomfort. None had a worsening of parkinsonism or other adverse events. Thirteen patients reported subjective improvements in bowel frequency (>3 times/week, 13) and difficult defecation (13). Mosapride shortened CTT of the left colon (P < 0.01) and the total colon (P < 0.05). During rectal filling, mosapride lessened the first sensation (P < 0.05) and augmented the amplitude in phasic rectal contraction. During defecation, mosapride augmented the amplitude in rectal contraction (P < 0.05) and lessened the volume of postdefecation residuals. The present study showed for the first time that mosapride citrate augmented lower gastrointestinal tract motility, as shown in CTT and videomanometry, and thereby ameliorated constipation in parkinsonian patients without serious adverse effects.
authors.affiliation: Department of Neurology, Chiba University, 1-8-1 Inohana Chuo-ku, Chiba 260-8670, Japan.
authors.forename: Zhi
authors.initials: Z
authors.lastname: Liu
authors.forename: Ryuji
authors.initials: R
authors.lastname: Sakakibara
authors.forename: Takeo
authors.initials: T
authors.lastname: Odaka
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Uchiyama
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Uchiyama
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Yamamoto
authors.forename: Takashi
authors.initials: T
authors.lastname: Ito
authors.forename: Masato
authors.initials: M
authors.lastname: Asahina
authors.forename: Kazuya
authors.initials: K
authors.lastname: Yamaguchi
authors.forename: Taketo
authors.initials: T
authors.lastname: Yamaguchi
authors.forename: Takamichi
authors.initials: T
authors.lastname: Hattori
mesh_terms: D000368:Aged; D001549:Benzamides / Q000737:chemistry / Q000627:therapeutic use*; D003106:Colon / Q000187:drug effects; D003248:Constipation / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D007839:Functional Laterality; D005772:Gastrointestinal Transit / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000737:chemistry / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000150:complications*; D058827:Serotonin 5-HT3 Receptor Agonists; D058828:Serotonin 5-HT4 Receptor Agonists; D016896:Treatment Outcome; D014741:Video Recording / Q000379:methods
chemical_list: D001549:Benzamides; D009025:Morpholines; D058827:Serotonin 5-HT3 Receptor Agonists; D058828:Serotonin 5-HT4 Receptor Agonists; C062720:mosapride